Spectral Lighting for Intestinal Failure
What You Need to Know Before You Apply
What is the purpose of this trial?
The goal of this exploratory n-of-1-study is to compare markers of metabolism in infants with intestinal failure between two lighting environments. Investigators are seeking to learn whether supplementing the lighting environment of infants with intestinal failure with blue and violet wavelengths of light will allow more efficient utilization of the nutrition provided to participants by influencing hormones involved in regulation of growth and development as compared to a conventional lighting environment.Pre-clinical studies suggest that violet and blue wavelengths of light are involved in molecular pathways that help regulate metabolic activity.
Do I need to stop my current medications for this trial?
The trial information does not specify whether participants need to stop taking their current medications. It is best to discuss this with the trial coordinators or your healthcare provider.
How is the treatment Spectral Lighting unique for intestinal failure?
Spectral Lighting is unique because it uses specific wavelengths of light to potentially enhance intestinal perfusion (blood flow) and oxygenation, which is different from traditional treatments that do not utilize light-based methods. This approach may offer a novel way to monitor and improve intestinal function by targeting the mucosal surface with visible light.12345
What data supports the effectiveness of the treatment Spectral Lighting for Intestinal Failure?
Research on lighting systems in neonatal intensive care units suggests that specific lighting conditions, like cycled light, can positively impact health. While this is not directly related to intestinal failure, it indicates that lighting can influence physiological processes, which might be relevant for Spectral Lighting's potential benefits.678910
Who Is on the Research Team?
James M Greenberg, MD
Principal Investigator
Children's Hospital Medical Center, Cincinnati
Are You a Good Fit for This Trial?
This trial is for infants diagnosed with or expected to have intestinal failure, who are at least 32 weeks gestational age and will likely stay in the hospital for over 9 weeks after joining the study.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants are exposed to alternating lighting environments to assess metabolic markers
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Spectral Lighting
Find a Clinic Near You
Who Is Running the Clinical Trial?
Children's Hospital Medical Center, Cincinnati
Lead Sponsor